Abaloparatide (Tymlos) vs ARA 290
Updated September 21, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of Abaloparatide (Tymlos) and ARA 290 (also searched as ARA 290 vs Abaloparatide (Tymlos)) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
Abaloparatide (Tymlos) centers on healing, while ARA 290 leans toward neuro. On indexed research, ARA 290 is ahead (Abaloparatide (Tymlos): 32 studies, Human clinical; ARA 290: 33, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •Abaloparatide (Tymlos) is strongest for healing; ARA 290 for neuro.
- •Evidence: Abaloparatide (Tymlos) Human clinical (32 studies) vs ARA 290 Human evidence (33).
- •Check the FDA-approval status chips above before assuming a legal use pathway.
Effect profiles, overlaid
At a glance
PTH1R Activation | Osteoporosis Treatment
Neuroprotection | Nerve regeneration
Abaloparatide (Tymlos) vs ARA 290: side-by-side
| Metric | Abaloparatide (Tymlos) | ARA 290 |
|---|---|---|
| Class | Healing | Neuro |
| Regulatory status | FDA-approved | Research use only |
| Evidence grade | Human clinical | Human evidence |
| Studies indexed | 32 | 33 |
| Research level | FDA Approved | Preclinical |
| Strongest effect | Healing & recovery | Neuro & mood |
| Healing & recovery | 4.0▲ | 4.0▲ |
| Muscle & body comp | 0.0 | 0.0 |
| Metabolic & appetite | 0.0 | 2.0▲ |
| Neuro & mood | 0.0 | 5.0▲ |
| Sleep & circadian | 0.0 | 0.0 |
| Inflammation & immune | 0.0 | 3.0▲ |
| Skin & aesthetics | 0.0 | 0.0 |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | Abaloparatide (Tymlos) | ARA 290 |
|---|---|---|
| Mechanism | PTH1R agonist | Modulates macrophage activity and promotes anti-inflammatory cytokine release |
| Route | Subcutaneous injection | Subcutaneous injection |
| Half-life | ~30 min | — |
| Time to peak | 4 hours | — |
| Duration of action | 24 hours | — |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is Abaloparatide (Tymlos)?
Abaloparatide (Tymlos) is a synthetic PTHrP analog and FDA-approved anabolic agent for osteoporosis, building bone via selective PTH1R activation.
Full Abaloparatide (Tymlos) profile, mechanism & studies →What is ARA 290?
ARA 290, also known as a peptide derived from the erythropoietin (EPO) molecule, has garnered attention for its potential therapeutic applications, particularly in the context of nerve regeneration and protection. The peptide is designed to mimic some of the beneficial effects of EPO without eliciting the same erythropoietic activity, which can lead to unwanted side effects such as increased blood viscosity and hypertension.
Full ARA 290 profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | Even | Both ~4.0/5 |
| Metabolic | ARA 290 | 2.0/5 effect signal |
| Neuro | ARA 290 | 5.0/5 effect signal |
| Inflammation | ARA 290 | 3.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack Abaloparatide (Tymlos) and ARA 290?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because at least one is a research-use compound, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
Abaloparatide (Tymlos) vs ARA 290: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
Abaloparatide (Tymlos) has 32 approved studies indexed (Human clinical), and ARA 290 has 33 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is Abaloparatide (Tymlos) or ARA 290 better?
It depends on your goal. Abaloparatide (Tymlos) is strongest for healing; ARA 290 for neuro. ARA 290 has more indexed studies (33). See the goal-by-goal breakdown above.
Is Abaloparatide (Tymlos) or ARA 290 better for weight loss?
ARA 290 shows the stronger metabolic & appetite profile (2.0/5) in the AI-assigned effect profile — though weight-loss outcomes depend on the individual and the evidence base.
Which has more research, Abaloparatide (Tymlos) or ARA 290?
Abaloparatide (Tymlos) has 32 approved studies indexed (Human clinical); ARA 290 has 33 (Human evidence). Higher counts mean more to read, not proven superiority.
Can you stack Abaloparatide (Tymlos) and ARA 290?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of Abaloparatide (Tymlos) vs ARA 290?
Abaloparatide (Tymlos): no community-reported effects logged yet. ARA 290: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is Abaloparatide (Tymlos) or ARA 290 FDA-approved?
Abaloparatide (Tymlos) is FDA-approved. ARA 290 is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is ARA 290 better than Abaloparatide (Tymlos)?
For neuro, ARA 290 has the edge; for healing, Abaloparatide (Tymlos) does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Approval status varies (see the chips at the top). FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed September 21, 2026.